Methylphenidate transdermal - Taho Pharma
Alternative Names: ADHD-TAH9901; Methylphenidate transdermal patch - Taho Pharma; TAH-9901Latest Information Update: 31 Jul 2023
At a glance
- Originator TAHO Pharmaceuticals
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Attention-deficit hyperactivity disorder
Most Recent Events
- 31 Jul 2023 Phase-I clinical trials in Attention-deficit hyperactivity disorder in Taiwan (Transdermal), prior to July 2023 (Taho Pharma pipeline, July 2023)